Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

Leiper, Keith, Martin, Kate, Ellis, Anthony, Subramanian, Sreedhar, Watson, Alastair J ORCID: https://orcid.org/0000-0003-3326-0426, Christmas, Steve E, Howarth, Deborah, Campbell, Fiona and Rhodes, Jonathan M (2011) Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut, 60 (11). pp. 1520-1526. ISSN 0017-5749

Full text not available from this repository. (Request a copy)


To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC).

Item Type: Article
Uncontrolled Keywords: adult,antibodies, monoclonal, murine-derived,antigens, cd19,antigens, cd20,b-lymphocytes,colitis, ulcerative,colon,female,glucocorticoids,humans,immunohistochemistry,immunosuppressive agents,lymphocyte count,middle aged,remission induction
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 07 Jul 2014 13:44
Last Modified: 23 Dec 2022 02:33
URI: https://ueaeprints.uea.ac.uk/id/eprint/48953
DOI: 10.1136/gut.2010.225482

Actions (login required)

View Item View Item